These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25533112)

  • 1. Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features.
    Rafi MA; Rao HZ; Luzi P; Luddi A; Curtis MT; Wenger DA
    Mol Genet Metab; 2015 Mar; 114(3):459-66. PubMed ID: 25533112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.
    Rafi MA; Rao HZ; Luzi P; Wenger DA
    Mol Ther; 2015 Nov; 23(11):1681-1690. PubMed ID: 26329589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease.
    Rafi MA; Rao HZ; Luzi P; Curtis MT; Wenger DA
    Mol Ther; 2012 Nov; 20(11):2031-42. PubMed ID: 22850681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2.
    Lin D; Fantz CR; Levy B; Rafi MA; Vogler C; Wenger DA; Sands MS
    Mol Ther; 2005 Sep; 12(3):422-30. PubMed ID: 15996520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS-targeted AAV5 gene transfer results in global dispersal of vector and prevention of morphological and function deterioration in CNS of globoid cell leukodystrophy mouse model.
    Lin DS; Hsiao CD; Liau I; Lin SP; Chiang MF; Chuang CK; Wang TJ; Wu TY; Jian YR; Huang SF; Liu HL
    Mol Genet Metab; 2011 Aug; 103(4):367-77. PubMed ID: 21620749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant.
    Karumuthil-Melethil S; Marshall MS; Heindel C; Jakubauskas B; Bongarzone ER; Gray SJ
    J Neurosci Res; 2016 Nov; 94(11):1138-51. PubMed ID: 27638599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy.
    Rafi MA; Zhi Rao H; Passini MA; Curtis M; Vanier MT; Zaka M; Luzi P; Wolfe JH; Wenger DA
    Mol Ther; 2005 May; 11(5):734-44. PubMed ID: 15851012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitigation of cerebellar neuropathy in globoid cell leukodystrophy mice by AAV-mediated gene therapy.
    Lin DS; Hsiao CD; Lee AY; Ho CS; Liu HL; Wang TJ; Jian YR; Hsu JC; Huang ZD; Lee TH; Chiang MF
    Gene; 2015 Oct; 571(1):81-90. PubMed ID: 26115766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease).
    Luzi P; Rafi MA; Zaka M; Curtis M; Vanier MT; Wenger DA
    Mol Genet Metab; 2001 Jul; 73(3):211-23. PubMed ID: 11461188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAVrh10 Gene Therapy Ameliorates Central and Peripheral Nervous System Disease in Canine Globoid Cell Leukodystrophy (Krabbe Disease).
    Bradbury AM; Rafi MA; Bagel JH; Brisson BK; Marshall MS; Pesayco Salvador J; Jiang X; Swain GP; Prociuk ML; ODonnell PA; Fitzgerald C; Ory DS; Bongarzone ER; Shelton GD; Wenger DA; Vite CH
    Hum Gene Ther; 2018 Jul; 29(7):785-801. PubMed ID: 29316812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy.
    Matthes F; Andersson C; Stein A; Eistrup C; Fogh J; Gieselmann V; Wenger DA; Matzner U
    Exp Neurol; 2015 Sep; 271():36-45. PubMed ID: 25956830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Engineered Galactosylceramidase Construct Improves AAV Gene Therapy for Krabbe Disease in Twitcher Mice.
    Pan X; Sands SA; Yue Y; Zhang K; LeVine SM; Duan D
    Hum Gene Ther; 2019 Sep; 30(9):1039-1051. PubMed ID: 31184217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy.
    Lee WC; Tsoi YK; Troendle FJ; DeLucia MW; Ahmed Z; Dicky CA; Dickson DW; Eckman CB
    FASEB J; 2007 Aug; 21(10):2520-7. PubMed ID: 17403939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of galactosylceramidase (GALC) expression in the twitcher mouse model of globoid cell leukodystrophy (GLD) is caused by nonsense-mediated mRNA decay (NMD).
    Lee WC; Tsoi YK; Dickey CA; Delucia MW; Dickson DW; Eckman CB
    Neurobiol Dis; 2006 Aug; 23(2):273-80. PubMed ID: 16759875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo.
    Meng XL; Shen JS; Watabe K; Ohashi T; Eto Y
    Mol Genet Metab; 2005 Apr; 84(4):332-43. PubMed ID: 15781194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraventricular administration of recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological improvements.
    Shen JS; Watabe K; Ohashi T; Eto Y
    Gene Ther; 2001 Jul; 8(14):1081-7. PubMed ID: 11526455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Galactosylceramidase Deficiency Causes Upregulation of Long Pentraxin-3 in the Central Nervous System of Krabbe Patients and
    Coltrini D; Chandran AMK; Belleri M; Poliani PL; Cominelli M; Pagani F; Capra M; Calza S; Prioni S; Mauri L; Prinetti A; Kofler JK; Escolar ML; Presta M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy.
    Hawkins-Salsbury JA; Shea L; Jiang X; Hunter DA; Guzman AM; Reddy AS; Qin EY; Li Y; Gray SJ; Ory DS; Sands MS
    J Neurosci; 2015 Apr; 35(16):6495-505. PubMed ID: 25904800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination HSCT and intravenous AAV-mediated gene therapy in a canine model proves pivotal for translation of Krabbe disease therapy.
    Bradbury AM; Bagel J; Swain G; Miyadera K; Pesayco JP; Assenmacher CA; Brisson B; Hendricks I; Wang XH; Herbst Z; Pyne N; Odonnell P; Shelton GD; Gelb M; Hackett N; Szabolcs P; Vite CH; Escolar M
    Mol Ther; 2024 Jan; 32(1):44-58. PubMed ID: 37952085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic rescue of Krabbe disease in the twitcher mouse.
    De Gasperi R; Friedrich VL; Perez GM; Senturk E; Wen PH; Kelley K; Elder GA; Gama Sosa MA
    Gene Ther; 2004 Aug; 11(15):1188-94. PubMed ID: 15164096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.